Testing chemotherapy with or without extra cancer medicines for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can sign written consent for the study.
- You are 21 years or older and have non-keratinizing nasopharyngeal cancer confirmed by lab testing.
- Your cancer must be EBV-positive, and your tumor must be measurable on scans.
- Your cancer stage must be III (with limited specific exceptions) or stage IVA, and you should not have had any prior cancer treatment.
- Your overall health/function should be good (ECOG score 0–1), and your organs must work well enough for treatment.
- You must be able to give blood for required study tests, and follow pregnancy/contraception rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial tests if an immunotherapy drug (adebrelimab) can help people with advanced nasopharyngeal cancer whose Epstein-Barr virus (EBV) DNA levels stay high or stable after initial chemotherapy. It aims to see if this personalized approach improves outcomes.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
Hear when a new Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.